<div id="readability-page-1"><p><span>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report)</span> had its price target reduced by Oppenheimer  from $26.00 to $21.00 in a report issued on Thursday,Benzinga reports. The firm currently has an &#34;outperform&#34; rating on the stock. Oppenheimer's price objective points to a potential upside of 376.19% from the stock's current price.</p><div><p><span></span><span>Get <strong>Larimar Therapeutics</strong> alerts:</span></p></div><p>A number of other research firms have also weighed in on LRMR. Guggenheim  reiterated a &#34;buy&#34; rating and set a $26.00 price objective on shares of Larimar Therapeutics in a research note on Tuesday, June 24th. Robert W. Baird decreased their price objective on shares of Larimar Therapeutics from $10.00 to $7.00 and set an &#34;outperform&#34; rating for the company in a research report on Tuesday. Citigroup  reiterated a &#34;buy&#34; rating on shares of Larimar Therapeutics in a research report on Tuesday, June 24th. JMP Securities cut their target price on shares of Larimar Therapeutics from $22.00 to $18.00 and set a &#34;market outperform&#34; rating for the company in a research note on Friday, August 15th. Finally, Wedbush lowered their price objective on Larimar Therapeutics from $15.00 to $11.00 and set an &#34;outperform&#34; rating on the stock in a report on Tuesday. Nine research analysts have rated the stock with a Buy rating,  According to MarketBeat, Larimar Therapeutics  has an average rating of &#34;Buy&#34; and a consensus target price of $16.71.</p><p><b>View Our Latest Stock Report on LRMR</b></p><h2>Larimar Therapeutics Trading Up 6.3%</h2><p>LRMR stock opened at $4.41 on Thursday. The company has a 50-day moving average price of $3.90 and a 200 day moving average price of $2.97. The stock has a market cap of $365.06 million, a PE ratio of -2.82 and a beta of 1.00. Larimar Therapeutics has a 12 month low of $1.61 and a 12 month high of $9.50. </p><p>Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.06.  Sell-side analysts forecast that  Larimar Therapeutics will post -1.15 EPS for the current year. </p><h2>Insider Activity at Larimar Therapeutics</h2><p>In related news, Director James E. Flynn purchased 9,375,000 shares of the business's stock in a transaction that occurred on Thursday, July 31st. The shares were purchased at an average cost of $3.20 per share, for a total transaction of $30,000,000.00. Following the purchase, the director directly owned 9,538,945 shares of the company's stock, valued at $30,524,624. The trade was a 5,718.38% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. 4.50% of the stock is owned by company insiders. </p><h2>Hedge Funds Weigh In On Larimar Therapeutics</h2><p>Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets purchased a new position in  Larimar Therapeutics during the fourth quarter worth about $25,000.  Savant Capital LLC purchased a new stake in shares of  Larimar Therapeutics in the second quarter valued at approximately $39,000.  Wealth Enhancement Advisory Services LLC acquired a new position in  Larimar Therapeutics during the second quarter worth $44,000.  Walleye Capital LLC purchased a new position in  Larimar Therapeutics in the first quarter worth $37,000.  Finally, Next Level Private LLC purchased a new stake in shares of  Larimar Therapeutics in the 2nd quarter worth about $58,000. Hedge funds and other institutional investors own  91.92% of the company's stock. </p><h2>Larimar Therapeutics Company Profile</h2> (Get Free Report)<p>Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Larimar Therapeutics</li><li>How to buy stock: A step-by-step guide for beginners </li><li>The New Brain of Business: UiPath Is Creating an AI Revolution</li><li>3 Fintech Stocks With Good 2021 Prospects</li><li>Buy The Dip Opportunity: Paychex Signals Rebound After Sell-Off</li><li>Large Cap Stock Definition and How to Invest</li><li>3 Lesser-Known Healthcare Names With Major Upside in Store</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TFJNUg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Larimar Therapeutics Right Now?</h2><p>Before you consider Larimar Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Larimar Therapeutics wasn't on the list.</p><p>While Larimar Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LRMR

<p>Oppenheimer has reduced its price target for Larimar Therapeutics (NASDAQ:LRMR) from $26.00 to $21.00 while maintaining an "outperform" rating. This new target suggests a potential upside of 376.19% from the current stock price. Other firms have also provided mixed ratings, with some maintaining buy ratings and others lowering their targets. Larimar's stock opened at $4.41, with a market cap of $365.06 million. The company focuses on developing treatments for rare diseases and recently reported better-than-expected quarterly earnings.</p>

Larimar Therapeutics (NASDAQ:LRMR) Price Target Cut to $21.00 by Analysts at Oppenheimer